PJP Prophylaxis Guidelines

Primary Prophylaxis Indications

• The Centers for Disease Control and Prevention recommends PJP prophylaxis in HIV-infected patients with CD4+ T-cell counts less than 200 cells/μL 1, 3
• Prophylaxis is also indicated for patients with constitutional symptoms such as thrush or unexplained fever, regardless of CD4+ count 1
• For patients who have recovered from a documented episode of PJP, prophylaxis should be continued indefinitely 1, 3

Dosing Options

• The American College of Physicians recommends one double-strength tablet (800 mg SMX/160 mg TMP) daily for PJP prophylaxis 2
• One double-strength tablet three times weekly (typically Monday-Wednesday-Friday) is also a recommended regimen 2
• For patients with TMP-SMX intolerance, alternative regimens include dapsone 100 mg daily 4, 2 and atovaquone 1500 mg daily 4, 2

Special Considerations

• The Centers for Disease Control and Prevention states that TMP-SMX is the first-line agent due to superior efficacy compared to alternatives 3, 2
• Common adverse effects of TMP-SMX include rash, pruritus, cytopenias, and transaminase elevations 1, 3
• For non-HIV immunocompromised patients on triple immunosuppressive therapy, prophylaxis with TMP-SMX 800/160 mg three times weekly is recommended 4, 5

Monitoring

• The Centers for Disease Control and Prevention recommends assessing patients for active pulmonary disease prior to initiating prophylaxis 1
• Regular monitoring for adverse effects, including complete blood counts with differential and platelet counts, is recommended 6
• For HIV patients, CD4+ counts should be monitored every 3-6 months 1, 3